Successful treatment with the fully human antibody panitumumab after a severe infusion reaction with cetuximab.

摘要: Aims and background. There are only limited data on the safety efficacy of pan itumumab in patients who experienced severe infusion reactions during cetuximab antibody therapy. Case report. We report case a 69-year-old woman with chemotherapy-refracto ry metastatic colorectal cancer received single-agent treatment but reaction first infusion, despite premedication corticosteroids/antihistamines. Cetuximab was discontinued panitumumab initiated approximately 14 days later (without premedication); no fusion occurred there rapid improvement her general condi tion. She partial response that sustained for 7 months before pro gression. Conclusions. This supports use chemotherapy-refractory suggests panitumum ab may be used some prior to cetuximab. Free full text available at www.tumorionline.it